Zydus Asked to Revise Phase III Trial Protocol for Cough Syrup FDC After CDSCO Panel Review
New Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has recommended key revisions to the Phase III clinical trial protocol for Zydus Healthcare Ltd's fixed-dose combination (FDC) of Dextromethorphan Hydrobromide IP 10 mg and Phenylephrine Hydrochloride IP 5 mg per 5 ml syrup.
The recommendations were made during the Pulmonary SEC meeting held on July 9, 2025, where the firm presented its Phase III clinical trial protocol along with a special invitee (Pediatrician), in line with earlier SEC advice dated June 11, 2025.
After detailed deliberation, the expert panel opined that:
“Patients below 18 years should be excluded from the study.”
“Patients with pre-existing cardiovascular and respiratory disease should be excluded from the study.”
The committee directed the firm to submit a revised Phase III clinical trial protocol to CDSCO for further review in accordance with these recommendations.
Dextromethorphan hydrobromide is a widely used cough suppressant, while phenylephrine hydrochloride functions as a nasal decongestant. The combination is commonly found in over-the-counter formulations for cough, cold, and flu symptom relief.
Also Read: Zydus Gets SEC Nod to Begin Phase IV Trial of Dydrogesterone ER for Habitual Miscarriage
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.